نتایج جستجو برای: decitabine

تعداد نتایج: 2165  

2016
Salvatore Serravalle Salvatore N Bertuccio Annalisa Astolfi Fraia Melchionda Andrea Pession

T-Acute Lymphoblastic Leukemia (T-ALL) remains a subgroup of pediatric ALL, with a lower response to standard chemotherapy. Some recent studies established the fundamental role of epigenetic aberrations such as DNA hypermethylation, to influence patients' outcome and response to chemotherapy. Moreover, L-asparaginase is an important chemotherapeutic agent for treatment of ALL and resistance to ...

2012
Josephine Aimiuwu Hongyan Wang Ping Chen Zhiliang Xie Jiang Wang Shujun Liu Rebecca Klisovic Alice Mims William Blum Guido Marcucci Kenneth K. Chan

5-Azacytidine (5-azaC) is an azanucleoside approved for myelodysplastic syndrome. Approximately 80%-90% of 5-azaC is believed to be incorporated into RNA, which disrupts nucleic acid and protein metabolism leading to apoptosis. A smaller fraction (10%-20%) of 5-azaC inhibits DNA methylation and synthesis through conversion to decitabine triphosphate and subsequent DNA incorporation. However, it...

2013
Jackie R. Bickenbach Ann Tomanek-Chalkley Susan Wiechert Michael C. Winter

Patient-specific cell replacement therapy is fast becoming the future of medicine, requiring safe, effective methods for reprogramming a patient's own cells. Previously, we showed that a single transient transfection with a plasmid encoding Oct4 was sufficient to reprogram human skin keratinocytes (HSKs), and that this transfection resulted in a decrease in global DNA methylation. In more recen...

Journal: :Blood 2004
Paul La Rosée Kara Johnson Amie S Corbin Eric P Stoffregen Erika M Moseson Stephanie Willis Michael M Mauro Junia V Melo Michael W Deininger Brian J Druker

Imatinib mesylate (Gleevec, formerly STI571) is an effective therapy for all stages of chronic myelogenous leukemia (CML). While responses in chronic-phase CML are generally durable, resistance develops in many patients with advanced disease. We evaluated novel antileukemic agents for their potential to overcome resistance in various imatinib-resistant cell lines. Using cell proliferation assay...

2013
Yushi Yao Jihao Zhou Lixin Wang Xiaoning Gao Qiaoyang Ning Mengmeng Jiang Jia Wang Lili Wang Li Yu

As one of the best known cancer testis antigens, PRAME is overexpressed exclusively in germ line tissues such as the testis as well as in a variety of solid and hematological malignant cells including acute myeloid leukemia. Therefore, PRAME has been recognized as a promising target for both active and adoptive anti-leukemia immunotherapy. However, in most patients with PRAME-expressing acute m...

Journal: :Cancer immunology research 2014
Kunle Odunsi Junko Matsuzaki Smitha R James Paulette Mhawech-Fauceglia Takemasa Tsuji Austin Miller Wa Zhang Stacey N Akers Elizabeth A Griffiths Anthony Miliotto Amy Beck Carl A Batt Gerd Ritter Shashikant Lele Sacha Gnjatic Adam R Karpf

The cancer-testis/cancer-germline antigen NY-ESO-1 is a vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase (DNMT) inhibitors may augment NY-ESO-1 vaccine therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of c...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2015
Can Küçük Xiaozhou Hu Bei Jiang David Klinkebiel Huimin Geng Qiang Gong Alyssa Bouska Javeed Iqbal Philippe Gaulard Timothy W McKeithan Wing C Chan

PURPOSE To identify tumor suppressor genes epigenetically silenced by promoter hypermethylation in extranodal natural killer cell lymphoma (NKCL). EXPERIMENTAL DESIGN Promoter methylation was analyzed with global and locus-specific methylation assays in NKCL cases and NK cell lines. Gene expression profiles were used to identify genes for which aberrant promoter methylation was associated wit...

2013
Kazuo Okemoto Kazue Kasai Benjamin Wagner Amy Haseley Hans Meisen Chelsea Bolyard Xiaokui Mo Allison Wehr Amy Lehman Soledad Fernandez Balveen Kaur Antonio Chiocca

Purpose:Oncolytic viruses (OV) based on herpes simplex virus type 1 (HSV1) are being used in clinical trials for a variety of cancers. The OV, rQNestin34.5, uses a nestin promoter/enhancer to selectively drive robust viral replication in malignant glioma cells. We have discovered that this promoter becomes extensively methylated in infected glioma cells, reducing OV efficacy. ExperimentalDesign...

Journal: :The Journal of clinical investigation 2015
Yogen Saunthararajah Mikkael Sekeres Anjali Advani Reda Mahfouz Lisa Durkin Tomas Radivoyevitch Ricki Englehaupt Joy Juersivich Kathleen Cooper Holleh Husseinzadeh Bartlomiej Przychodzen Matthew Rump Sean Hobson Marc Earl Ronald Sobecks Robert Dean Frederic Reu Ramon Tiu Betty Hamilton Edward Copelan Alan Lichtin Eric Hsi Matt Kalaycio Jaroslaw Maciejewski

BACKGROUND Mutational inactivation in cancer of key apoptotic pathway components, such as TP53/p53, undermines cytotoxic therapies that aim to increase apoptosis. Accordingly, TP53 mutations are reproducibly associated with poor treatment outcomes. Moreover, cytotoxic treatments destroy normal stem cells with intact p53 systems, a problem especially for myeloid neoplasms, as these cells reverse...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید